Stratos Wealth Partners LTD. acquired a new stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,957 shares of the biopharmaceutical company’s stock, valued at approximately $415,000.

Other hedge funds have also recently made changes to their positions in the company. Fiduciary Trust Co. acquired a new position in shares of Alexion Pharmaceuticals in the second quarter valued at about $111,000. Huntington National Bank increased its holdings in shares of Alexion Pharmaceuticals by 1,084.6% in the second quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock valued at $131,000 after purchasing an additional 987 shares during the period. Penserra Capital Management LLC increased its holdings in shares of Alexion Pharmaceuticals by 13.0% in the second quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 144 shares during the period. Dupont Capital Management Corp acquired a new position in shares of Alexion Pharmaceuticals in the third quarter valued at about $156,000. Finally, Acadian Asset Management LLC purchased a new stake in shares of Alexion Pharmaceuticals in the second quarter worth about $160,000. 96.71% of the stock is currently owned by institutional investors and hedge funds.

Shares of Alexion Pharmaceuticals, Inc. (ALXN) opened at $110.87 on Friday. Alexion Pharmaceuticals, Inc. has a fifty-two week low of $96.18 and a fifty-two week high of $149.34. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.96 and a quick ratio of 2.51. The company has a market capitalization of $24,769.47, a P/E ratio of 22.67, a P/E/G ratio of 1.21 and a beta of 1.22.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, beating the consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The firm had revenue of $859.00 million during the quarter, compared to analysts’ expectations of $864.34 million. During the same quarter last year, the firm earned $1.23 earnings per share. The business’s revenue for the quarter was up 7.5% on a year-over-year basis. research analysts forecast that Alexion Pharmaceuticals, Inc. will post 4.81 EPS for the current year.

In other Alexion Pharmaceuticals news, Director Ann M. Veneman sold 835 shares of the firm’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total transaction of $121,751.35. Following the completion of the sale, the director now owns 5,480 shares of the company’s stock, valued at $799,038.80. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Julie O’neill sold 11,160 shares of the firm’s stock in a transaction on Monday, August 28th. The stock was sold at an average price of $140.00, for a total value of $1,562,400.00. Following the sale, the executive vice president now directly owns 26,704 shares of the company’s stock, valued at approximately $3,738,560. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,490 shares of company stock valued at $2,337,251. Insiders own 4.35% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2017/11/19/stratos-wealth-partners-ltd-takes-position-in-alexion-pharmaceuticals-inc-alxn.html.

A number of analysts have recently commented on the company. SunTrust Banks, Inc. restated a “buy” rating and issued a $180.00 target price (up previously from $170.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. Deutsche Bank AG restated a “buy” rating and issued a $158.00 target price (up previously from $153.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. BMO Capital Markets restated an “outperform” rating and issued a $173.00 target price (up previously from $168.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. BidaskClub upgraded Alexion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. Finally, Evercore ISI assumed coverage on Alexion Pharmaceuticals in a research note on Wednesday, August 16th. They issued an “in-line” rating and a $137.00 target price on the stock. Six investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have issued a strong buy rating to the stock. Alexion Pharmaceuticals currently has an average rating of “Buy” and an average target price of $154.01.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.